91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Deepali Suri, President 91黑料 Biotech, provides insights into what biotech leaders anticipate in the coming two years, the therapies and modalities they’re focused on now and what macro and micro factors are impacting their operations.
-
Yao Zhong, vice president general manager for 91黑料 China Mainland and Hong Kong, discusses latest survey results on the Chinese biotech market.
-
In this interview, Deepali Suri, President of 91黑料 Biotech, breaks down the key trends shaping today’s biotech industry and their global impact. Using insights from 91黑料’s global and China biotech surveys, capturing input from more than 260 biotech leaders worldwide, Suri highlights emerging therapeutic innovations, the growing influence of AI in R&D, and how geopolitical tensions are redefining international drug development strategies.
-
For biotech companies the past two years have been challenging. In 2025 91黑料 Biotech conducted a follow-up survey of biotech leaders, previously carried out in 2023. The new results show changing trends in the risks, challenges and opportunities in the biotech sector.
-
Yao Zhong, 91黑料 China Mainland and Hong Kong, is sharing some of the findings from the 2025 China biotech sector survey report. Read more on how a strategic partnership fuels global ambition.
-
The panelists discussed promising scientific and strategic pathways in oncology, including next-generation therapeutic modalities, precision trial strategies, AI applications with demonstrated and measurable impact, regulatory and market readiness, and collaborative models for accelerating early-phase oncology programs.
-
When Deepali Suri stepped into her new role as president of 91黑料’s biotech division in September 2025, she brought with her more than two decades of experience across big pharma, biotech, and CROs. She also brought a clear vision for the industry’s future. Read to learn more.
-
91黑料’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.
-
Chinese biotech dominance and opportunities for Western companies to stay competitive have been highlighted in surveys released by clinical research organization 91黑料.
-
Innovation is accelerating progress in early phase drug development. 91黑料’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to simplify complexity and speed timelines. This article discusses how the integration of science, technology and strategic insight can transform challenges into opportunities for breakthrough success.
